Cytokinetics, Incorporated
CYTK
$77.22
$2.413.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 450.60% | 376.56% | 2,609.26% | 2,635.74% | 412.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 450.60% | 376.56% | 2,609.26% | 2,635.74% | 412.21% |
| Cost of Revenue | 15.66% | 22.11% | 22.05% | 18.37% | 7.17% |
| Gross Profit | 9.15% | -1.71% | 3.38% | 6.83% | -2.55% |
| SG&A Expenses | 46.05% | 32.03% | 29.32% | 34.08% | 34.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.56% | 26.24% | 25.06% | 24.25% | 16.57% |
| Operating Income | -13.19% | -14.17% | -9.21% | -8.08% | -13.59% |
| Income Before Tax | -34.84% | -33.15% | -30.45% | -11.19% | -15.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.84% | -33.15% | -30.45% | -11.19% | -15.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.84% | -33.15% | -30.45% | -11.19% | -15.96% |
| EBIT | -13.19% | -14.17% | -9.21% | -8.08% | -13.59% |
| EBITDA | -13.11% | -14.32% | -10.20% | -9.01% | -14.53% |
| EPS Basic | -29.45% | -24.35% | -17.08% | 4.66% | 1.75% |
| Normalized Basic EPS | -10.41% | -5.20% | 1.68% | 4.66% | 1.75% |
| EPS Diluted | -29.45% | -24.35% | -17.08% | 4.66% | 1.75% |
| Normalized Diluted EPS | -10.41% | -5.20% | 1.68% | 4.66% | 1.75% |
| Average Basic Shares Outstanding | 4.17% | 6.96% | 11.24% | 16.59% | 17.99% |
| Average Diluted Shares Outstanding | 4.17% | 6.96% | 11.24% | 16.59% | 17.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |